KRAS and neoplasm: We found that palbociclib/ MSC2504877 synergy existed in SW480 (APC p.Q1338* homozygous, KRAS p.G12V homozygous and amplified), SW620 (APC Q1338* homozygous, KRAS p.G12V homozygous and amplified) and SW403 (APC mutation p.N125K;p.F1197fs;p.S1278* heterozygous, KRAS mutation p.G12C heterozygous) CRC tumour cell lines (Fig. 5G).